# Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations

> **NCT04511533** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 101 (actual)

## Conditions studied

- Metastatic Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Dacomitinib

## Key facts

- **NCT ID:** NCT04511533
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-27
- **Primary completion:** 2022-10-15
- **Final completion:** 2022-11-08
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2024-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04511533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04511533, "Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04511533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*